Unknown

Dataset Information

0

Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.


ABSTRACT: Neoadjuvant pemetrexed plus cisplatin was administered, followed by extrapleural pneumonectomy (EPP) and hemithoracic radiation (RT), to assess the feasibility and efficacy of trimodality therapy in stage I to III malignant pleural mesothelioma.Requirements included stage T1-3 N0-2 disease, no prior surgical resection, adequate organ function (including predicted postoperative forced expiratory volume in 1 second > or = 35%), and performance status 0 to 1. Patients received pemetrexed 500 mg/m(2) plus cisplatin 75 mg/m(2) for four cycles. Patients without disease progression underwent EPP followed by RT (54 Gy). The primary end point was pathologic complete response (pCR) rate.Seventy-seven patients received chemotherapy. All four cycles were administered to 83% of patients. The radiologic response rate was 32.5% (95% CI, 22.2 to 44.1). Fifty-seven patients proceeded to EPP, which was completed in 54 patients. Three pCRs were observed (5% of EPP). Forty of 44 patients completed irradiation. Median survival in the overall population was 16.8 months (95% CI, 13.6 to 23.2 months; censorship, 33.8%). Patients completing all therapy had a median survival of 29.1 months and a 2-year survival rate of 61.2%. Radiologic response of complete or partial response was associated with a median survival of 26.0 months compared with 13.9 months for patients with stable disease or progressive disease (P = .05).This multicenter trial showed that trimodality therapy with neoadjuvant pemetrexed plus cisplatin is feasible with a reasonable long-term survival rate, particularly for patients who completed all therapy. Radiologic response to chemotherapy, but not sex, histology, disease stage, or nodal status, was associated with improved survival.

SUBMITTER: Krug LM 

PROVIDER: S-EPMC3646305 | biostudies-literature | 2009 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.

Krug Lee M LM   Pass Harvey I HI   Rusch Valerie W VW   Kindler Hedy L HL   Sugarbaker David J DJ   Rosenzweig Kenneth E KE   Flores Raja R   Friedberg Joseph S JS   Pisters Katherine K   Monberg Matthew M   Obasaju Coleman K CK   Vogelzang Nicholas J NJ  

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090413 18


<h4>Purpose</h4>Neoadjuvant pemetrexed plus cisplatin was administered, followed by extrapleural pneumonectomy (EPP) and hemithoracic radiation (RT), to assess the feasibility and efficacy of trimodality therapy in stage I to III malignant pleural mesothelioma.<h4>Patients and methods</h4>Requirements included stage T1-3 N0-2 disease, no prior surgical resection, adequate organ function (including predicted postoperative forced expiratory volume in 1 second > or = 35%), and performance status 0  ...[more]

Similar Datasets

| S-EPMC4901093 | biostudies-literature
| S-EPMC3722081 | biostudies-literature
| S-EPMC8246920 | biostudies-literature
| S-EPMC6656469 | biostudies-literature
| S-EPMC9571799 | biostudies-literature
| S-EPMC6267825 | biostudies-other
| S-EPMC8692272 | biostudies-literature
| S-EPMC7711390 | biostudies-literature
| S-EPMC3148430 | biostudies-literature